November 21, 2026Funding-Series DMedTech

Galvanize Therapeutics Raises $130M Series D for Pulsed-Field Tumor Ablation

No heat, no cold, just electricity in short pulses. Galvanize Therapeutics, a Redwood City medical device company, raised a $130M oversubscribed Series D led by HealthQuest Capital to sell its pulsed electric field ablation system. The round was announced Monday Nov 16 and is a catch-up here: it ranked third on Crunchbase's weekly biggest-rounds list published inside this window. HealthQuest founder and managing partner Garheng Kong joins the board. Olympus Innovation Ventures and Braidwell are new investors; Sofinnova Partners, Norwest and Elevage Medical Technologies returned. No valuation disclosed. Release: https://www.prnewswire.com/news-releases/galvanize-therapeutics-raises-130-million-in-oversubscribed-series-d-financing-to-accelerate-commercial-growth-and-advance-pef-innovation-302939618.html

What pulsed electric field ablation does, plainly: instead of burning or freezing tissue, short high-voltage pulses open the cell membranes and kill the cells, while the scaffolding around them survives better. Galvanize's Aliya system is cleared by the FDA for surgical ablation of soft tissue. The new Aliya EX generator, cleared about six months ago, can make ablation zones about 20 mm wide on top of the older 10 mm zones, which widens the set of patients who qualify.

The money pays for three things: selling Aliya, bringing RheOx to the US market, and next-generation devices. RheOx delivers the same kind of energy into the lung airways to reduce mucus-producing cells in chronic bronchitis and has been on sale in Europe since 2022. The company raised $100M at its 2022 merger with Gala Therapeutics and Galaxy Medical, and another $100M in 2025. Coverage: https://www.medtechdive.com/news/galvanize-raises-130m-to-advance-pulsed-electric-field-ablation/874861/

My read: this is a commercial-stage round, not a science bet. The device is cleared, the bigger generator is in hospitals, and the question for $130M is purely whether surgeons switch. Medtech rounds this size this late usually mean the next step is an exit, not another round.
← Previous
BrightAI Raises $97M Series A for AI That Listens to Pumps and Power Poles
Next β†’
Marrow Therapeutics Launches With $173M Series A and B to Deliver Drugs Straight to Bone Marrow
← Back to all articles

Comments

Loading...
>_